We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
1. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
-
2. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
4. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
5. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
6. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
7. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
8. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
9. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
10. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
12. Cancer vaccines
- Dr. Elias Sayour
-
13. The regulation of cell therapy
- Prof. Moutih Rafei
-
14. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
15. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
16. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
17. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
18. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
19. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
20. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
21. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
23. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
24. MassBank development and future
- Dr. Emma L. Schymanski
-
25. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
26. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
27. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
28. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
29. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
-
30. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
32. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
33. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
-
34. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
36. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
37. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
38. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
39. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
40. Combating the HIV epidemic
- Prof. William Blattner
-
41. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
42. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
43. Pediatric cancer testing
- Prof. Joshua Schiffman
-
44. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
45. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
46. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
47. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
Topics Covered
- Proteomic aging clock
- Mortality prediction
- Biological aging
- Plasma proteins
- Statistical machine-learning models
Biography
Dr. Austin Argentieri is a researcher in the Analytic and Translational Genetics Unit at Massachusetts General Hospital, with academic appointments at Harvard Medical School and the Broad Institute. He is also a member of the Center for Genomic Medicine at Massachusetts General Hospital. He previously completed his PhD and postdoctoral research at the Big Data Institute at the University of Oxford. His research is focused on large-scale analyses to understand the genetic, biological, and environmental determinants of human aging and age-related diseases.
Links
Series:
Categories:
External Links
Talk Citation
Argentieri, M.A. (2025, May 29). Decoding aging: how a proteomic clock predicts mortality and disease across populations [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 2, 2025, from https://doi.org/10.69645/NUIL7547.Export Citation (RIS)
Publication History
- Published on May 29, 2025
Financial Disclosures
- Dr. M. Austin Argentieri has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Decoding aging: how a proteomic clock predicts mortality and disease across populations
Published on May 29, 2025
17 min
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Dr.
Austin Argentieri,
thank you very much for
taking the time to discuss
your recent publication with
colleagues in nature medicine.
The publication describes
the development of
a proteomic age clock
using plasma proteins
to estimate biological age
and predict age-related
diseases and
mortality across
diverse populations.
Could you start by summarizing
your research goals
and the main approach that
your team took to meet them?
Dr. Argentieri: Absolutely.
Thank you for having me.
It's a pleasure
to discuss these.
The motivation for
our study comes from
the fact that
age-related diseases are
some of the major
killers globally.
If you look at the global
population above 70 years old,
nine out of the top
ten global causes of
death are all
age-related diseases.
Our motivation was
to try to see if
we could find some
biology that's common to
these diseases that
might help us develop
very effective and strategic
precision medicine
and preventative health tools.
It just so happens
that if you look
at the history of
the field of aging
and if you look at what
we know so far about
the biological
hallmarks of aging that
many different age-related
chronic diseases share
the same aging biology and
the same aging-related
biological mechanisms.
Of course, loss of proteostasis
and protein stability is
one of the core biological
hallmarks of aging.
So we started with
this idea that
if we could capture something
about aging biology through,
in this case, plasma proteins,
it might allow us to capture
something that's a common
biological aging
signal across many of
these different common
chronic diseases
Hide